Caris Life Sciences, Inc.CAIEarnings & Financial Report
Caris Life Sciences is a leading precision medicine biotech company specializing in advanced molecular profiling for oncology. It provides actionable genomic and molecular insights to oncologists to personalize cancer treatment plans, and partners with biopharmaceutical firms to accelerate novel cancer drug discovery and development, serving customers across North America, Europe, and key Asia-Pacific markets.
Revenue
$100.0M
Gross Profit
N/A
Operating Profit
$-67.0M
Net Profit
$-66.2M
Gross Margin
N/A
Operating Margin
-67.0%
Net Margin
-66.2%
YoY Growth
N/A
EPS
$-2.54
Caris Life Sciences, Inc. Q2 FY2024 Financial Summary
Caris Life Sciences, Inc. reported revenue of $100.0M for Q2 FY2024, with a net profit of $-66.2M (-66.2% margin).
Key Financial Metrics
| Total Revenue | $100.0M |
|---|---|
| Net Profit | $-66.2M |
| Gross Margin | N/A |
| Operating Margin | -67.0% |
| Report Period | Q2 FY2024 |
Caris Life Sciences, Inc. Quarterly Revenue & Net Profit History
Caris Life Sciences, Inc. results over the last 4 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2025 | $216.8M | +113.4% | $24.3M | 11.2% |
| Q2 FY2025 | $181.4M | +81.3% | $-71.8M | -39.6% |
| Q3 FY2024 | $101.6M | — | $-67.7M | -66.6% |
| Q2 FY2024 | $100.0M | — | $-66.2M | -66.2% |
Income Statement
| Q2 2024 | Q3 2024 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|
| Revenue | $100.0M | $101.6M | $181.4M | $216.8M |
| YoY Growth | N/A | N/A | 81.3% | 113.4% |
Balance Sheet
| Q2 2024 | Q3 2024 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|
| Assets | N/A | N/A | $955.1M | $984.6M |
| Liabilities | N/A | N/A | $502.2M | $506.2M |
| Equity | $-2.36B | $-2.44B | $452.9M | $478.4M |
Cash Flow
| Q3 2025 | |
|---|---|
| Operating CF | $62.4M |